Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | PKLR | P30613 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29800886 | 1.00 | LMNA (0.59) | LMNAL3MBTL1ATMNPC1RAB9A | |
| SCHEMBL758323 | 0.83 | ATM (0.66) | LMNAL3MBTL1ATMNPC1RAB9A | |
| SCHEMBL2611773 | 0.79 | LMNA (0.59) | LMNAL3MBTL1ATMNPC1RAB9A | |
| SCHEMBL8243698 | 0.79 | LMNA (0.59) | LMNAL3MBTL1ATMNPC1RAB9A | |
| SCHEMBL193715 | 0.78 | LMNA (0.63) | LMNAL3MBTL1ATMF2PRSS1 | |
| SCHEMBL19259040 | 0.78 | LMNA (0.56) | LMNAL3MBTL1ATMNPC1RAB9A | |
| SCHEMBL1952494 | 0.78 | LMNA (0.68) | LMNAL3MBTL1ATMF2PRSS1 | |
| SCHEMBL31252815 | 0.78 | SNCA (0.64) | LMNAL3MBTL1ATMMEN1KMT2A | |
| Methanesulfonamide SCHEMBL11803937 | 0.78 | LMNA (0.88) | LMNAL3MBTL1ATMMEN1KMT2A | |
| SCHEMBL5480078 | 0.78 | SNCA (0.64) | LMNAL3MBTL1ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714716-B1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | SOCPRA SCIENCES SANTE ET HUMAINES S E C (CA) | 2018-04-11 | — | — | EP | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| EP-2152672-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-02-17 | — | — | EP | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| WO-2008141843-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008141843-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MAP4K2, MAP3K20, MAP3K2 | LMNA 3935/4885L3MBTL1 2436/4885ATM 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.